This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomePrevnar 20®Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine)Broad pneumococcal defenseMOABurden of diseaseIPDCAPACIP recommendationsACIP recommendationsACIP recommendationsPatient profilesClinical studies

Clinical studies

Built on PCV13Study 1 resultsStudy 1 designStudy 1 safetyStudy 6 resultsStudy 6 designStudy 6 safetyCAPiTAAdministrationAccess & supportAccess & supportMedicareCommercial health plansEventsMaterialsVideos
Prescribing InformationIndicationsPatient SiteOrder Prevnar 20®
Certain adult patients may be at increased risk for pneumococcal pneumonia1,2Certain adult patients may be at increased risk for pneumococcal pneumonia1,2

Choose one dose of Prevnar 20® to help protect eligible adult patients

For patients age 18-64 with certain underlying medical conditions,* there is increased risk of pneumococcal pneumonia compared to healthy individuals in the same age range.

See patient profiles

Mary is 65 and healthy


Medical history:

  • Healthy 
  • Pneumococcal vaccine-naïve

Age alone is a risk factor for pneumococcal pneumonia1,2

Mary is at a 6.1X greater risk for pneumococcal pneumonia vs healthy adults age 18 to 64 because of her age1,2

One dose of Prevnar 20® alone can help protect your eligible adult patients age 65 or older3,4


When discussing Prevnar 20 with your eligible patients, tell them that severe allergic reaction to any component of Prevnar 20 or to diphtheria toxoid is a contraindication.

Sean is 35 and living with asthma


Medical history:

  • Asthma 
  • Pneumococcal vaccine-naïve

Sean is at a 5.7X greater risk for pneumococcal pneumonia vs healthy adults in the same age range because he has asthma1,2

One dose of Prevnar 20® alone can help protect your eligible adult patients age 19-64 with certain underlying medical conditions or other risk factors3,4*

When discussing Prevnar 20 with your eligible patients, tell them that severe allergic reaction to any component of Prevnar 20 or to diphtheria toxoid is a contraindication.

Alcoholism, chronic heart/liver/lung disease, cigarette smoking, diabetes, chronic renal failure,† nephrotic syndrome,† iatrogenic immunosuppression,† generalized malignancy,† human immunodeficiency virus,† Hodgkin disease,† leukemia,† lymphoma,† multiple myeloma,† solid organ transplant,† congenital or acquired asplenia,† sickle cell disease or other hemoglobinopathies,† CSF leak, cochlear implant, or congenital or acquired immunodeficiencies.4†Immunocompromising conditions.Lisa is 47 and takes an immunosuppressant medication


Medical history:

  • Rheumatoid arthritis and treated with an immunosuppressant medication
  • Unknown pneumococcal vaccination status

Lisa is at a 17.3X greater risk for pneumococcal pneumonia vs healthy adults in the same age range because she takes an immunosuppressant medication1,2

One dose of Prevnar 20® alone can help protect your eligible adult patients age 19-64 with certain underlying medical conditions or other risk factors3,4*

When discussing Prevnar 20 with your eligible patients, tell them that safety and immunogenicity data on Prevnar 20 are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20.

Alcoholism, chronic heart/liver/lung disease, cigarette smoking, diabetes, chronic renal failure,† nephrotic syndrome,† iatrogenic immunosuppression,† generalized malignancy,† human immunodeficiency virus,† Hodgkin disease,† leukemia,† lymphoma,† multiple myeloma,† solid organ transplant,† congenital or acquired asplenia,† sickle cell disease or other hemoglobinopathies,† CSF leak, cochlear implant, or congenital or acquired immunodeficiencies.4†Immunocompromising conditions.Roger is 59 and living with diabetes


Medical history:

  • Diabetes
  • Unknown pneumococcal vaccination status

Roger is at a 5.3X greater risk for pneumococcal pneumonia vs healthy adults in the same age range because he has diabetes1,2

One dose of Prevnar 20® alone can help protect your eligible adult patients age 19-64 with certain underlying medical conditions or other risk factors3,4*

When discussing Prevnar 20 with your eligible patients, tell them that for Prevnar 20, in adults age 18 or older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in adults age 18 through 59.

Alcoholism, chronic heart/liver/lung disease, cigarette smoking, diabetes, chronic renal failure,† nephrotic syndrome,† iatrogenic immunosuppression,† generalized malignancy,† human immunodeficiency virus,† Hodgkin disease,† leukemia,† lymphoma,† multiple myeloma,† solid organ transplant,† congenital or acquired asplenia,† sickle cell disease or other hemoglobinopathies,† CSF leak, cochlear implant, or congenital or acquired immunodeficiencies.4†Immunocompromising conditions.Sophia is 64 and living with chronic heart disease


Medical history:

  • Chronic heart disease
  • Previously vaccinated with PPSV23

Sophia is at a 7.9X greater risk for pneumococcal pneumonia vs healthy adults in the same age range because she has chronic heart disease1,2

One dose of Prevnar 20® alone can help protect your eligible adult patients age 19-64 with certain underlying medical conditions or other risk factors3,4*

When discussing Prevnar 20 with your eligible patients, tell them that for Prevnar 20, in adults age 18 or older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in adults age 18 through 59.

Alcoholism, chronic heart/liver/lung disease, cigarette smoking, diabetes, chronic renal failure,† nephrotic syndrome,† iatrogenic immunosuppression,† generalized malignancy,† human immunodeficiency virus,† Hodgkin disease,† leukemia,† lymphoma,† multiple myeloma,† solid organ transplant,† congenital or acquired asplenia,† sickle cell disease or other hemoglobinopathies,† CSF leak, cochlear implant, or congenital or acquired immunodeficiencies.4†Immunocompromising conditions.ReferencesACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; CSF=cerebrospinal fluid; PCV13=Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]); PPSV23=23-valent pneumococcal polysaccharide vaccine.Alcoholism, chronic heart/liver/lung disease, cigarette smoking, diabetes, chronic renal failure,† nephrotic syndrome,† iatrogenic immunosuppression,† generalized malignancy,† human immunodeficiency virus,† Hodgkin disease,† leukemia,† lymphoma,† multiple myeloma,† solid organ transplant,† congenital or acquired asplenia,† sickle cell disease or other hemoglobinopathies,† CSF leak, cochlear implant, or congenital or acquired immunodeficiencies.4†Immunocompromising conditions.
References:Pelton SI, Bornheimer R, Doroff R, Shea KM, Sato R, Weycker D. Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization. Clin Infect Dis. 2019;68(11):1831-1838. Data on file. Pfizer Inc. Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information, Wyeth Pharmaceuticals LLC, 2022. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109-117.
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
Manufactured by Wyeth Pharmaceuticals LLC.
© 2023 Pfizer Inc.

All rights reserved.

Marketed by Pfizer Inc.
January 2023
ACIP recommendations With the most serotypes in a pneumococcal conjugate vaccine, you can help protect your eligible adult patients.3 Explore additional protection Loading A single dose of Prevnar 20 can help protect your eligible patients against pneumococcal pneumonia.3 See the administration details Loading Order Prevnar 20 for your office by registering for Prime. Get started Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2023 Pfizer Inc. All rights reserved.

PP-PNR-USA-0821
You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-MCL-USA-0367

​​​​​​​
INDICATIONS AND SELECT SAFETY INFORMATION
  • Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
  • The indication of Prevnar 20® for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
  • Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

SELECT SAFETY INFORMATION
 
  • Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20®, Prevnar 13®, or to diphtheria toxoid is a contraindication
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20® 
Important Safety Information
  • Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20®, Prevnar 13®, or to diphtheria toxoid is a contraindication
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
  • For Prevnar 20®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in adults 18 through 59 years of age  
  • For Prevnar 13®, in adults 18 years of age and older, the most commonly reported solicited adverse reactions (>5%) were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.

Please click for Prevnar 13® Full Prescribing Information.Indications
  • Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
  • The indication of Prevnar 20® for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
  • Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diptheria CRM197 Protein]) is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine